City
Epaper

Hyderabad-based Biological E to get mRNA technology from WHO to produce COVID-19 vaccines

By ANI | Published: April 04, 2022 7:21 PM

Hyderabad-based vaccine manufacturer Biological E on Monday announced that it has been selected as a recipient of mRNA technology from the World Health Organisation (WHO) technology transfer hub.

Open in App

Hyderabad-based vaccine manufacturer Biological E on Monday announced that it has been selected as a recipient of mRNA technology from the World Health Organisation (WHO) technology transfer hub.

After examining a number of proposals from India, the WHO's Advisory Committee on Vaccine Product Development (ACPDV) selected Biological E Limited as a recipient of mRNA technology from the WHO technology transfer hub. WHO and their partners will work with the Indian government to develop a roadmap and put in place the necessary training and support for Biological E to start producing mRNA vaccines as soon as possible, said Biological E.

Primarily set up to address the COVID-19 emergency, the WHO mRNA technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities.

mRNA vaccines use a messenger RNA created in a laboratory to teach the human cells how to produce a protein that in turn initiates an immune response inside the body against a particular disease. The immune response will fight the actual virus as it gets into the body.

At present, India has no COVID-19 vaccine made on an mRNA platform.

Over the development, Biological E Managing Director Mahima Datla said, "We are excited about this remarkable milestone in our efforts to produce affordable vaccines for the world. We are very pleased with the trust that WHO places in our organisation, which adheres to the standards set by the WHO. This is also a reflection of our world-class processes, scale and effectiveness."

"Biological E has been investing in mRNA technologies since last year. This new technology will definitely strengthen our resolve to develop and manufacture more vaccines in future. This partnership with WHO will enhance our ability to develop next-generation mRNA vaccines that could be more suitable globally and expand the reach of vaccines availability worldwide," Datla said.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Who's advisory committee on vaccine product developmentMahima datlaWorld Health Organisation
Open in App

Related Stories

LifestyleWorld Health Day 2024: Date, Theme, History, Significance and Importance

MaharashtraMumbai: Yashwantrao Chavan Centre's National Award Announced to Dr. Soumya Swaminathan

InternationalNon-Smokers Gain Ground: Global Tobacco Use Declines by 110 Million, New Gen Says No

HealthWhat’s Disease X? The Next Possible Global Health Threat After COVID-19

MaharashtraCM Eknath Shinde Assures Preparedness Amid JN 1 Variant Concerns

National Realted Stories

NationalPM Modi Continues Meditation at Vivekananda Rock Memorial in Kanyakumari, Offers Water to Sun and Chants Mantras (Watch Video)

NationalPunjab registers 9.64 pc polling in first two hours

NationalDelhi: Fire Breaks Out at Kashmiri Gate Metro Police Station; Watch Videos

NationalECI registers 10.58 pc polling in first few hours of voting in Bihar

NationalKerala Government Denies Animal Sacrifice 'Shatru Bhairavi Yaga' Allegation by Karnataka Deputy CM DK Shivakumar